Compare FMC Corp (FMC) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FMC Corp vs GeneDx Holdings Corp — how do they compare? FMC Corp trades at $10.48 (market cap $1.31B), while GeneDx Holdings Corp trades at $81.98 (market cap $2.32B). The key difference: GeneDx Holdings Corp is the larger of the two by market cap, and FMC Corp pays a 3.06% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| FMC | WGS | |
|---|---|---|
Market Cap | $1.31B | $2.32B |
Sector | Basic Materials | Technology |
52-Week High | $40.69 | $167.51 |
52-Week Low | $10.01 | $34.51 |
Enterprise Value | $5.11B | $2.35B |
Dividend Yield | 3.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FMC trades at $10.59, up 0.38% today, with a bearish technical signal from moving averages. The stock shows mixed earnings beats but faces severe profitability challenges, with a net income margin of -84.83% and negative ROE of -91.47% for 2025. Recent news highlights revenue declines and cost management efforts, including a $400 million investment from Tessenderlo Group to reduce debt.
The outlook remains cautious due to persistent losses and competitive pressures in agricultural sciences. Upside exists if operational improvements and debt reduction stabilize finances, but high volatility and margin pressures pose significant risks to shareholder value.
GeneDx Holdings Corp. (WGS) trades at $77.08, up 10.76% today, showing strong momentum despite negative profitability metrics. The stock exhibits bullish technical signals with support at $72 and resistance at $80. Recent Q2 2026 earnings beat expectations with $0.01 EPS versus -$0.19 estimate, while revenue reached $114.4 million. However, the company faces significant challenges with a -23.4% net income margin and ongoing securities class action litigation.
Investment outlook remains cautiously optimistic given strong analyst support (90.9% buy rating) and $79.25 consensus price target. Key opportunities include growing genomic testing volumes and improved operational efficiency, while risks center on profitability challenges, legal liabilities, and high valuation multiples that may not justify current fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About FMC Corp
FMC is a pure-play crop chemical company. The company has diversified its sales to create a balanced crop chemical portfolio across geographies and crop exposure. Through acquisitions, FMC is now one of the five largest patented crop chemical companies and will continue to develop new products, with a focus on biologicals, through its research and development pipeline.
Read more on FMC →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
